Bayer R&D, Production Job Cuts Finalize Restructuring
This article was originally published in The Pink Sheet Daily
Executive Summary
Company plans to eliminate 110 jobs at West Haven, Conn. facility and 440 in Germany, resulting in cost savings of over $170 mil. R&D projects in anti-infectives and urology could be out-licensed.
You may also be interested in...
Bayer Spring Investor Conference March 16 Will Stress 2004 Financial Upturn
Restructuring is seen as a key factor in Bayer's improved performance. Its U.S. oncology business and ex-U.S. Levitra promotion are among likely topics for updates at the investor meeting.
Bayer Spring Investor Conference March 16 Will Stress 2004 Financial Upturn
Restructuring is seen as a key factor in Bayer's improved performance. Its U.S. oncology business and ex-U.S. Levitra promotion are among likely topics for updates at the investor meeting.
Bayer To Retain Kogenate Line Following Plasma Unit Spin-Off
Company divests plasma products business to NPS BioTherapeutics under a $590 mil. agreement. Bayer will receive 10% equity in NPS, a new corporation formed by Cerebus Capital Management and Ampersand Ventures.